I don't know about others, but I'd guess one of the concerns the market may have is that the increased in head count will put pressure on them to continue to improve their sales growth. They have also renewed their focus on R&D, taking back the breast development stuff from establishment labs for example, so all that is going to increase costs.
Stepping on the pedal to accelerate sales increases the potential benefits if you can bring more sales forward, but increases risks if those sales increases don't keep coming but your cost base is significantly higher.
Ann: 1H22 Results Webcast details, page-11
-
- There are more pages in this discussion • 24 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add PNV (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$2.29 |
Change
-0.010(0.43%) |
Mkt cap ! $1.580B | |||
| Open | High | Low | Value | Volume |
| $2.33 | $2.34 | $2.24 | $2.151M | 944.0K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 9090 | $2.27 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $2.29 | 15253 | 5 |
View Market Depth
| Last trade - 16.10pm 15/07/2024 (20 minute delay) ? |
| PNV (ASX) Chart |